SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

USFDA conducts inspection at units of Aurobindo Pharma’s arm

17 Nov 2023 Evaluate

The United States Food and Drug Administration (USFDA) has conducted a Pre-Approval Inspection (PAI) at Unit-I & III, Formulation manufacturing facility, of APL Healthcare, a wholly owned subsidiary of Aurobindo Pharma, situated at Telangana, from November 13 to 17, 2023.  The inspection closed with zero observations and a classification of ‘No Action Indicated’ (NAI).

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.


Aurobindo Pharma Share Price

1552.05 -0.75 (-0.05%)
02-Jul-2026 11:13 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1880.30
Dr. Reddys Labs. 1345.50
Cipla 1462.50
Zydus Lifesciences 1100.10
Lupin 2391.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: